We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Realignment Includes Critical Path Office, Revised Safety Structure
CDER Realignment Includes Critical Path Office, Revised Safety Structure
November 11, 2005
The FDA's proposed realignment of the Center for Drug Evaluation and Research (CDER) calls for the creation of a new office dedicated to the agency's Critical Path Initiative, as well as a major restructuring of the center's drug safety activities.